Zai Lab Ltd.

Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. Its products include Zejula, Optune, Qinlock, and Nuzyra. The company was founded by Samantha Ying Du and Marietta Wu in April 2014 and is headquartered in Shanghai, China.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Autohome

DingDong Cayman Ltd

JD.com

Li Auto Inc.

China has its share of problems, yet China stocks appear to be surging this week.

Why China Stocks Are Surging This Week

AbbVie

Alnylam Pharmaceuticals

Amgen

Biogen

Karuna Therapeutics Inc

Pfizer

Recent clinical successes and M&A could bring interest back to biotechnology, especially among mid-capitalization names with derisked or approved products. Restructuring, corporate activity, and COVID-19 revenues have significantly improved the funding positions of many large biopharma companies, providing ample dry powder for M&A.

Deal Activity Could Jumpstart Biotechnology

KE Holdings

Trip.com

Weibo

KE Holdings Inc - ADR (NYSE: BEKE), Trip.com Group Ltd (NASDAQ: TCOM), Weibo Corp (NASDAQ: WB) and Zai Lab Ltd - ADR

What In The World Is Going On With KE Holdings, Trip.com Group, Weibo And Zai Lab Shares? - KE Holdings (NYSE:BEKE), Zai Lab (NASDAQ:ZLAB), Trip.com Group (NASDAQ:TCOM), Weibo (NASDAQ:WB)

-- Company to Host Conference Call and Webcast on November 10, 2022, at 8:00 a.m. ET -- Company to Host Conference Call and Webcast on November 10, 2022, at 8:00 a.m. ET

Zai Lab to Announce Third Quarter 2022 Financial Results on November 9, 2022

Outlines Company's ESG Strategy through its Trust for Life Commitments Outlines Company's ESG Strategy through its Trust for Life Commitments

Zai Lab Launches its first Trust Report

Seagen

BOTHELL, Wash. & SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN), a world leader and pioneer in antibody-drug conjugate (ADC) therapies, and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage global biopharmaceutical company, today announced an exclusive collaboration and license agreement for the development and commercialization of TIVDAK® (tisotumab vedotin-tftv) in mainland China, Hong Kong, Macau, and Taiwan. TIVDAK is the f

Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv)

New subgroup analysis of the Phase 3 PRIME study reveals improvement in efficacy outcomes for ZEJULA® (niraparib) maintenance treatment when started within 12 weeks after first-line platinum-based chemotherapy (1LCT) New subgroup analysis of the Phase 3 PRIME study reveals improvement in efficacy outcomes for ZEJULA® (niraparib) maintenance treatment when started within 12 weeks after first-line platinum-based chemotherapy (1LCT)

Zai Lab to Present Analysis of the Impact of Timing for ZEJULA® (niraparib) Maintenance Treatment in Newly Diagnosed Advanced Ovarian Cancer at the 2022 International Gynecologic Cancer Society Meeting

Zai Lab Limited (NASDAQ:ZLAB ) Q2 2022 Earnings Conference Call August 10, 2022 8:00 AM ET Company Participants Samantha Du - Founder, Chairperson and Chief Executive Officer Josh Smiley - Chief Operating Officer Billy Cho - Chief Financial Officer Alan Sandler - President, Head of Global Development, Oncology Harald Reinhart - President, Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases Jonathan Wang - Chief Business Development Conference Call Participants Michael Yee - Jefferies Yigal Nochomovitz - Citi Anupam Rama - J.P. Morgan Jonathan Chang - SVB Leerink Ziyi Chen - Goldman Sachs Seamus Fernandez - Guggenheim Yang Huang - Credit Suisse Operator Hello, ladies and gentlemen, thank you for standing by and welcome to Zai Lab's Second Quarter 2022 Financial Results Conference Call.

Zai Lab Limited's (ZLAB) CEO Samantha Du on Q2 2022 Results - Earnings Call Transcript

Zai Lab (ZLAB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Zai Lab (ZLAB)

Trial met primary endpoint, with KarXT demonstrating a statistically significant 9.6-point reduction in PANSS Total Score compared to placebo at Week 5 (p

Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia

The mean of analysts' price targets for Zai Lab Limited Unsponsored ADR (ZLAB) points to a 144.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think Zai Lab Limited Unsponsored ADR (ZLAB) Could Surge 145%: Read This Before Placing a Bet

Bilibili

Schrodinger 

Zhihu

SHANGHAI , July 24, 2022 /PRNewswire/ -- Qiming Venture Partners' portfolio company InventisBio (SHSE: 688382), a leading company in innovative drug development, today listed on the Science and Technology Innovation Board (the "STAR Market") of the Shanghai Stock Exchange. The issue price is CNY 18.12 per share, representing a market cap of CNY 10.419 billion.

Qiming's Portfolio Company InventisBio Lists on STAR Market

Company to Host Conference Call and Webcast on August 10, 2022, at 8:00 a.m. ET Company to Host Conference Call and Webcast on August 10, 2022, at 8:00 a.m. ET

Zai Lab to Announce Second Quarter 2022 Financial Results on August 9, 2022

SHANGHAI, SAN FRANCISCO, and CAMBRIDGE, Mass., July 17, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, announced, effective today, that its ordinary shares traded on The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”) are now included in the Shanghai-Hong Kong Stock Connect program. Similarly, Zai Lab's ordinary shares traded on the Hong Kong Stock Exchange have been included in the Shenzhen-Hong Kong Stock Connect Program since June of 2022 when the Company's dual primary listing on both Nasdaq and the Hong Kong Stock Exchange became effective. Both Stock Connect Programs are anticipated to increase the access that eligible investors in mainland China have to Zai Lab and its shares.

Zai Lab Announces Inclusion of its Ordinary Shares in Two Stock Connect Programs

Efgartigimod alfa injection is the first accepted BLA submission of an FcRn antagonist for gMG patients in China Efgartigimod alfa injection is the first accepted BLA submission of an FcRn antagonist for gMG patients in China

Zai Lab Announces Acceptance by China's NMPA of the BLA for Efgartigimod for Patients with Generalized Myasthenia Gravis

–   First company to Convert from Secondary to Primary Listing Status in Hong Kong

Zai Lab Announces Primary Listing on the Main Board of The Stock Exchange of Hong Kong Limited

Commercial stage global biotech company Zai Lab (NASDAQ: ZLAB) stock has cratered (-82%) from a 52-week high of $178.91.

Zai Lab Stock Has Fallen to Value Levels

-- Breakthrough Therapy Designations granted for ROS1-positive non-small cell lung cancer (NSCLC) patients pretreated with one prior line of ROS1 tyrosine kinase inhibitor (TKI) with or without prior chemotherapy

Zai Lab Announces Breakthrough Therapy Designations Granted for Repotrectinib in China

Confirmed objective response rate was 50% for patients treated with TTFields together with standard-of-care chemotherapy

Zai Lab and Novocure Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced the presentation of a new subgroup data analysis from the Phase 3 PRIME study (NCT03709316) for niraparib in women in China with ovarian cancer at the upcoming 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 3-7, 2022. Since patient response to chemotherapy is associated with ovarian cancer prognosis, this subgroup analysis explores the treatment effect of niraparib maintenance therapy in patients with advanced ovarian cancer based on first-line platinum-based chemotherapy response.

Zai Lab to Present New PRIME Subgroup Analysis for Niraparib in Ovarian Cancer at 2022 ASCO Annual Conference

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that management from Zai Lab will be presenting at the following investor conferences in June:

Zai Lab Announces Upcoming Presentations at June Investor Conferences

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., May 20, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that, due to the public health impact of the coronavirus (COVID-19) pandemic and the recent pandemic-related restrictions in Shanghai, the format of the 2022 Annual General Meeting of Shareholders (Annual Meeting) of Zai Lab Limited has been changed, and the Annual Meeting will be held in a virtual meeting format only. The purpose of the Annual Meeting is to consider and vote on the matters described in the Proxy Statement. As previously announced, the Annual Meeting will be held on June 22, 2022 at 8:00 a.m. (U.S. Eastern Time) / 8:00 p.m. (Shanghai and Hong Kong Time).

Zai Lab Announces Change to Virtual 2022 Annual General Meeting of Shareholders to be Held on June 22, 2022

Start Time: 08:00 January 1, 0000 8:48 AM ET Zai Lab Limited (NASDAQ:ZLAB ) Q1 2022 Earnings Conference Call May 11, 2022, 08:00 AM ET Company Participants Samantha Du - Founder, Chairperson and CEO Billy Cho - CFO Alan Sandler - President, Head of Global Development, Oncology Harald Reinhart - President, Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases Jonathan Wang - Chief Business Development Conference Call Participants Michael Yee - Jefferies Yigal Nochomovitz - Citigroup Anupam Rama - JPMorgan Jonathan Chang - SVB Securities Ziyi Chen - Goldman Sachs Yang Huang - Credit Suisse Operator Hello, ladies and gentlemen. Thank you for standing by.

Zai Lab Limited (ZLAB) CEO Samantha Du on Q1 2022 Results - Earnings Call Transcript

Company to Host Conference Call and Webcast on May 11, 2022, at 8:00 a.m. ET Company to Host Conference Call and Webcast on May 11, 2022, at 8:00 a.m. ET

Zai Lab Announces First Quarter 2022 Financial Results and Corporate Updates

- Study met primary endpoint, demonstrating a higher proportion of sustained platelet response with VYVGART treatment compared to placebo (p=0.0316); responders observed across patient types regardless of prior therapy or disease severity

Zai Lab Partner argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia

News for Zai Lab Ltd. Stock (ZLAB)